Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Financial Report January – June 2021

Continued strong demand with solid performance Demand for LEAX products and services remained strong in the second quarter of 2021 despite stressed global supply chains causing interruptions in our customer schedules. Net sales for the second quarter amounted to SEK 466.2 million (279.4), which is an increase of 66.9% compared to last year. The increase in net sales is explained by market recovery from last year’s Covid-19 effects, higher deliveries within our key Automotive and Commercial Vehicle programs and good demand from customers in other end markets. Solid financial performance

Half Year Report Scandinavian Enviro Systems AB (publ) January – June 2021

Realizing our plans step by step.N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Q2 2021 · Net revenues for the period were MSEK 0.5 (0.2) · Earnings after tax for the period were MSEK -15.3 (-11.9) · Earnings per share for the period (before dilution) was SEK -0.03 (-0.05) · Cash flow for the period after investments was MSEK -15.6 (-11.4) · Michelin’s new racing tyres has better performance and less climate impact due to recovered

Crunchfish publishes half-year report for 2021

Today, Crunchfish AB (“Crunchfish”) publishes the company’s half-year report for the second quarter and first six months 2021. Below is a brief summary of the report.Group financials 2021-04-01 2020-04-01 2021-01-01 2020-01-01 2021-06-30 2020-06-30 2021-06-30 2020-06-30 Net sales (SEK) 916,575 2,330,489 2,017,787 4,278,383Profit or loss -8,629,724 -6,886,491 -16,395,669 -13,377,109before tax (SEK)Earnings per -0.30 -0.25 -0.58 -0.50share (SEK)Equity-assets 48.4% 86.2% 48.4%

Changes to Atrium Ljungberg’s company management – Martin Lindqvist is leaving

Martin Lindqvist, CFO at Atrium Ljungberg, is leaving his job after five years at the company.Martin Lindqvist has worked as the CFO of Atrium Ljungberg since 2016 and has been part of its executive management. He has decided to leave the company as the role of CFO will be changing. “During his time at the company, Martin has made a real contribution to the development and success of Atrium Ljungberg. I wish him all the very best for the future,” says Annica Ånäs, CEO of Atrium Ljungberg. Martin Lindqvist is leaving his job with immediate effect. The CEO, Annica Ånäs, will take on the

Interim report Q2, 2021

Second quarter · Net sales amounted to MSEK 14.1 (2.7) · EBITDA* amounted to MSEK -1.5 (-5.9) · EBIT amounted to MSEK -21.9 (-8.9)  · EBT amounted to MSEK -23.8 (12.2**) · Earnings per share before dilutions amounted to -0.08 (0.13) · SpectrumOne announces outcome of Rights Issue; 93 % subscription rate and SpectrumOne will receive proceeds amounting to approximately SEK 157 million before costs · SpectrumOne acquires Ampilio AB to merge with SpectrumOne’s subsidiaries The Trigger Company and BizWell Sweden AB · SpectrumOne increases its holding in Eniro to 29.5%

Divio Technologies AB (Publ) has increased subscription revenue by 48% and reduced the loss with 52%

Divio Technologies AB (Publ) has made a strong start to 2021, with a new sales team, and a new sales and marketing strategy, and growth continues to increase steadily. Subscription revenue has improved by 48% compared with the same period last year and net sales increased by 28%, and the figure is 40% if currency exchange effects are excluded. The company also reduced the loss with 52%.Due to the half year report, Divio Technologies will broadcast a presentation via Zoom on Monday 30/8 at 10:00 where CEO Jon Levin will present the report, viewers will also have the opportunity to ask

Inhalation Sciences Sweden AB (publ) releases Q2 Report 2021

(Stockholm, Sweden, 26, August, 2021) Inhalation Sciences AB announces that the company's Q2 Report for 2021 (in Swedish) is now available on the company's website.For more information please visit: http://inhalation.se/investors/finansiella-rapporter/ Summary of the interim report ISAB submitted an application for the clinical validation of PreciseInhale in early April and received approval from the Swedish Medical Products Agency to begin the study at the end of May 2021. All 12 patients are now recruited, and the study is scheduled to be finalised before the end of the year. The

Delårsrapport 1 JANUARI – 30 JUNI 2021 FLOWSCAPE TECHNOLOGY AB (publ), ORG.Nr. 556725-4866

Styrelsen och verkställande direktören för Flowscape Technology AB avger härmed rapport för perioden januari – juni 2021. Belopp anges i tusentals kronor. Siffror inom parentes avser motsvarande period föregående år.Januari – juni 2021 i korthet, koncern FÖRSTA HALVÅRET (JANUARI - JUNI) · Nettoomsättningen uppgick till 14 960 (14 483) TSEK · Rörelseresultat före avskrivningar uppgick till 61 (431) TSEK · Resultat efter finansiella poster uppgick till -11 834 (-13 119) TSEK · Kassaflödet uppgick till 637 (11 513) TSEK · Resultat per aktie efter finansiella poster uppgick

Scandic strengthens commercial management team

Tess Mattisson, Head of E-commerce & Customer Digital Development, and Marcus Hammarström, Head of Marketing, have been recruited to join Scandic Hotels’ commercial management team to strengthen and develop the company’s digital innovation and branding journey.Tess Mattisson has most recently worked at Choice Hotels International as Senior Director, Sales & Marketing. She also has experience from a number of management positions in commercial growth, e-commerce and change management within transitioning from analog to digital on an international level.- It’s fantastic to be joining

Forxiga approved in Japan for CKD

26 August 2021 07:05 BST Forxiga approved in Japan for the treatment of chronic kidney disease in patients with and without type-2 diabetes Approval marks an important transformation in the treatment of more than 13 million people suffering from chronic kidney disease in Japan AstraZeneca's Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The approval by Japan's Ministry of Health, Labour and Welfare (MHLW) is based on

Alzinova AB interim report January – June 2021

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the period January –June 2021.Six months, January – June 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -3,641,239 SEK (-2,898,387 SEK). · Earnings per share amounted to -0.23 SEK (-0.38 SEK). · Equity ratio amounted to 93.7% (92.6%) Three months, April – June 2021 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2,179,986 SEK (-1,123,481 SEK). · Earnings per share amounted to -0.14

Agilyx Announces Appointment of Chief Commercial Officer

TIGARD, Oregon, USA – August 26, 2021 – Agilyx Corporation  (Agilyx), a wholly owned subsidiary of Agilyx AS (Euronext Growth (Oslo): “AGLX”) and a pioneer in the advanced recycling of post-use plastics, announced today that Carsten Larsen  has been appointed chief commercial officer and senior vice president of Business Development for Agilyx, effective September 1, 2021, replacing Bill Cooper  who has joined Cyclyx LLC  as senior vice

Aker ASA: Enters partnership with SalMar to create world leading offshore farming operations

Aker ASA (“Aker”) announced today that it has entered a strategic partnership with SalMar ASA (“SalMar”) to establish a global offshore aquaculture company. The new joint company, SalMar Aker Ocean AS (“SalMar Aker Ocean”), will operate within offshore fish farming, including offshore and semi-offshore, combining Aker and SalMar’s industry experience, leading competence in salmon production, software, and cleantech to create the world’s most reliable and intelligent offshore farming operations with the highest requirements for fish welfare and a zero-emissions value chain ambition.“The

Baltic Sea at the heart of Caverion

Caverion Corporation Article 26 August 2021 at 9.00 a.m. EESTBaltic Sea at the heart of Caverion The Baltic Sea is a beautiful seascape with thousands of islands and a diverse ecosystem connecting the countries and cultures surrounding it. Every shore it touches is a home to Caverion; in many ways, it is our geographical heart. You can support efforts to protect the Baltic Sea by visiting our Smart City . Repairing and protecting the fragile ecosystem The Baltic Sea is one of the most polluted seas in the world. Each summer, blue-green

American Shipping Company ASA - Ex dividend today

Lysaker, 26 August 2021 Reference is made to the Company's Q2 2021 report, regarding the Board's authorization to pay a quarterly dividend of USD 0.10 per share to the shareholders of AMSC on record as of 27 August 2021.  The shares in American Shipping Company ASA will be traded ex dividend USD 0.10 as from today, 26 August 2021.  The NOK amount per share will be 0.8872 and will be paid on or about 3 September 2021.  The dividend is classified as a return of paid in capital. *** About American Shipping Company ASA: Established in 2005 and listed on the OSE, AMSC is a ship

ALXN1840 Wilson Phase III met primary endpoint

26 August 2021 07:00 BST ALXN1840 FoCus Phase III trial in Wilson disease met primary endpoint demonstrating improvement in copper mobilisation from tissues ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. The primary endpoint

Interim report April - June 2021

Gothenburg, August 26, 2021 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2021.Important events during the second quarter · In May, Vicore[1] announced that it had entered into a collaboration agreement with Alex Therapeutics for the development of a digital therapeutic (DTx) for patients living with idiopathic pulmonary fibrosis (IPF). · In June, Vicore announced that it had received approval from the U.S. Food and Drug Administration (FDA) to start the pivotal phase 3 trial with C21 in COVID-19. Important events after the period · No

Half-Year Financials, January 1 – June 30 2021

Faron Pharmaceuticals Oy (“Faron”) Faron Reports Half-Year Financials, January 1 – June 30, 2021 Significant progress made in H1 2021 including acceleration of most advanced pipeline assets - Bexmarilimab and Traumakine[Ò] August 26, 2021 at 7:00 am BST / 9:00 am EEST January – June 2021 in short/ Summary of January – June 2021 · Bexmarilimab shows compelling antitumor activity in multiple advanced solid tumor types as a monotherapy with strongest disease control rate, DCR (30.0% - 40.0%), observed in cutaneous melanoma, gastric cancer, cholangiocarcinoma and

BioInvent International AB: Interim report January-June 2021

“We are very pleased we have reached a second collaboration with MSD (Merck) that supports the expansion of the ongoing clinical trial program with our anti-TNFR2 antibody BI-1808. We are excited about the potential synergistic activity of BI-1808 in combination with pembrolizumab and this agreement supports the strong interest elicited by our broadening pipeline of anti-cancer antibodies.”- CEO Martin Welschof on the new agreement with Merck. Events in the quarter • BioInvent received IND approval for Phase 1/2a trial of anti-TNFR2 antibody BI-1808. • BioInvent and Transgene

SAGAX COMPLETES TAP ISSUE OF BOND LOAN 2021/2029

AB Sagax (publ) has, as under its EMTN programme, issued senior unsecured bonds of EUR 200 million with maturity in 2029. The issue is part of bond loan 2021/2029 (ISIN XS2342227837) with an aggregate amount of EUR 500 million after the tap issue. The bonds were issued at a price of 101.024 per cent which corresponds to a fixed annual yield of 0.86 per cent. The proceeds will be used for the company’s operating activities. For further information, please contact CEO David Mindus, telephone +46 8 545 83 540. About Sagax AB Sagax is a property company whose business concept is

Quickbit partners with Bank Frick for acquiring services

Quickbit has entered into an agreement with Bank Frick and adds another acquiring partner for card-to-crypto transactions. Bank Frick is an enterprising bank specialising in cutting-edge blockchain banking services. Adding Bank Frick as an acquiring partner supports Quickbits growth ambitions and lowers over time Quickbits transaction and introducer costs.The agreement offers Quickbit attractive terms and helps Quickbit lower its transaction and introducer costs over time. Bank Frick is an enterprising bank which offers a range of services designed for financial intermediaries and

Net Trading Group Interim Report Q2 2021

Net Trading Group NTG AB (publ) Interim report 1 January–30 June 2021The Board of Directors and the CEO of Net Trading Group NTG AB (publ) hereby submit the interim report for the first half of 2021. Summary of Group for the May–June 2021 period ·  Net sales amounted to kSEK 83 (–) ·  Operating loss amounted to kSEK -6,244 (–) ·  Diluted earnings per share SEK -0.01 (–) ·  Cash and cash equivalents at period end amounted to kSEK 4,694 (–) Summary of Parent Company for the April–June 2021 period · Net sales amounted to kSEK 0 (-55) · Operating loss amounted

IRRAS AB publishes Interim Report for the period, January to June 2021

Commercial Growth Continues“Q2 2021 marks the fourth consecutive quarter of growth for IRRAS despite the challenges of the COVID-19 pandemic, and the company is positioned to continue this positive growth trajectory." “This is an exciting time for IRRAS as our forward progress accelerates. A record number of patients were treated with our products during Q2, and published clinical data and surgeon feedback both support our company’s positive impact on critically ill patients.” Will Martin, President and CEO of IRRAS Second Quarter, April – June 2021, Results · Net revenue

There are no items matching the current filter
There are no more items matching the current filter
Back to top